Insider Selling: Blueprint Medicines Corp (BPMC) Major Shareholder Sells 30,000 Shares of Stock

Blueprint Medicines Corp (NASDAQ:BPMC) major shareholder Mark J. Levin sold 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 16th. The stock was sold at an average price of $40.88, for a total transaction of $1,226,400.00. Following the sale, the insider now owns 116,444 shares in the company, valued at approximately $4,760,230.72. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Blueprint Medicines Corp (NASDAQ:BPMC) traded up 0.12% during midday trading on Monday, reaching $41.41. 283,990 shares of the company’s stock were exchanged. The firm’s market capitalization is $1.37 billion. The firm’s 50 day moving average is $36.01 and its 200 day moving average is $31.51. Blueprint Medicines Corp has a 52 week low of $13.27 and a 52 week high of $42.42.

Blueprint Medicines Corp (NASDAQ:BPMC) last posted its quarterly earnings data on Thursday, March 9th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.76) by $0.01. Blueprint Medicines Corp had a negative net margin of 270.30% and a negative return on equity of 55.22%. The firm had revenue of $7.69 million for the quarter, compared to the consensus estimate of $6.31 million. During the same quarter in the prior year, the company posted ($0.58) earnings per share. The company’s revenue for the quarter was up 65.9% compared to the same quarter last year. On average, equities analysts anticipate that Blueprint Medicines Corp will post ($3.49) earnings per share for the current year.

Insider Buying and Selling by Quarter for Blueprint Medicines Corp (NASDAQ:BPMC)

Your IP Address:

Several institutional investors have recently bought and sold shares of the stock. Norges Bank bought a new position in Blueprint Medicines Corp during the fourth quarter valued at about $701,000. Opaleye Management Inc. increased its position in Blueprint Medicines Corp by 12.1% in the fourth quarter. Opaleye Management Inc. now owns 880,000 shares of the company’s stock valued at $24,684,000 after buying an additional 95,000 shares during the period. AQR Capital Management LLC bought a new position in Blueprint Medicines Corp during the fourth quarter valued at about $289,000. Perceptive Advisors LLC bought a new position in Blueprint Medicines Corp during the fourth quarter valued at about $7,680,000. Finally, Deerfield Management Co. increased its position in Blueprint Medicines Corp by 754.6% in the fourth quarter. Deerfield Management Co. now owns 1,842,415 shares of the company’s stock valued at $51,680,000 after buying an additional 1,626,829 shares during the period. Hedge funds and other institutional investors own 59.51% of the company’s stock.

A number of equities research analysts have commented on BPMC shares. Wedbush restated an “outperform” rating and set a $41.00 target price (down previously from $43.00) on shares of Blueprint Medicines Corp in a research note on Tuesday, November 29th. Goldman Sachs Group Inc upgraded shares of Blueprint Medicines Corp from a “neutral” rating to a “buy” rating and set a $52.00 target price on the stock in a research note on Monday, March 13th. Cowen and Company restated a “buy” rating and set a $33.19 target price (down previously from $38.33) on shares of Blueprint Medicines Corp in a research note on Monday, December 5th. Morgan Stanley started coverage on shares of Blueprint Medicines Corp in a research note on Wednesday, February 15th. They set an “overweight” rating and a $45.00 target price on the stock. Finally, Zacks Investment Research cut shares of Blueprint Medicines Corp from a “buy” rating to a “hold” rating in a research note on Tuesday, February 7th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $39.40.

Blueprint Medicines Corp Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.

5 Day Chart for NASDAQ:BPMC

Receive News & Ratings for Blueprint Medicines Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Nike Suspends Relationship with Maria Sharapova
Nike Suspends Relationship with Maria Sharapova
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Ron Washington Leaves Texas Rangers Due to an Affair
Ron Washington Leaves Texas Rangers Due to an Affair
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Tony Stewart Case Going to the Grand Jury
Tony Stewart Case Going to the Grand Jury
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder


Leave a Reply

 
© 2006-2017 Web Breaking News.